Navigation Links
Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
Date:8/26/2008

SEATTLE, Aug. 26 /PRNewswire/ -- Omeros Corporation today announced the publication of the results from a Phase 1/Phase 2 trial investigating OMS103HP in arthroscopic anterior cruciate ligament (ACL) reconstruction surgery. OMS103HP is an investigational drug product that is added to arthroscopic irrigation solution and is designed to improve postoperative knee function and motion, reduce postoperative pain and allow patients an earlier return to work. The article titled "Novel Drug Product to Improve Joint Motion and Function and Reduce Pain After Arthroscopic Anterior Cruciate Ligament Reconstruction" appeared in the June 2008 edition of Arthroscopy: The Journal of Arthroscopic and Related Surgery.

The article reports on a prospective, double-blind, vehicle-controlled study of 30 evaluable patients undergoing arthroscopic allograft ACL reconstruction. Patients were randomized across two arms to receive either standard arthroscopic irrigation solution or the same solution with OMS103HP added to it. Patients were monitored for safety, and efficacy endpoints assessed over the 30-day postoperative period included measurements of knee function and motion, leg muscle strength, pain and return to work.

Results of the study demonstrated a statistically significant improvement in knee function, range of motion, quadriceps and hamstring muscle strength, pain management and return to work in OMS103HP-treated patients. The incidence of adverse events and abnormal clinical laboratory values for OMS103HP and the control arm were similar.

"We are pleased that Arthroscopy, a well-respected and peer-reviewed journal, chose to publish these clinical results obtained using OMS103HP, the most clinically advanced of our PharmacoSurgery product candidates," said Gregory A. Demopulos, M.D., Chairman and CEO of Omeros. "We look forward to completing our ongoing Phase 3 clinical program further evaluating the safety and efficacy of OMS103HP."

OMS103HP is a proprietary combination of active pharmaceutical ingredients with known anti-inflammatory, analgesic and vasoconstrictive activities. If approved, OMS103HP will be the first commercially available drug product for the improvement of function following arthroscopic surgery.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. For more information on Omeros, visit the Company's Web site at http://www.omeros.com.


'/>"/>
SOURCE Omeros Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016   Click here ... Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent ... a definitive agreement to acquire Valley Campus Pharmacy, ... ("TNH"), a leading specialty pharmacy that provides individualized ... California . In 2015, TNH generated approximately ...
(Date:4/28/2016)... -- The blood testing market in China ... and The Freedonia Group in a recent report.  The ... healthcare research firm said that China ... and in improving testing at the provincial level.   The ... Blood Testing Market in China , which utilized ...
(Date:4/28/2016)... , April 28, 2016   Acsis , ... announced that leading IT market research and advisory firm ... in the IDC MarketScape: Worldwide Pharmaceutical Track and Trace ... The report provides an assessment of the capabilities and ... and trace software market. Logo - ...
Breaking Medicine Technology:
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... ... advocating optimistic healthcare awareness and author of best seller "LOVE, MEDICINE and MIRACLES") ... Radio Monday, May 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, ...
(Date:4/29/2016)... ... , ... Coast Dental Fort Stewart is celebrating its grand opening with an ... Furniture Mall at 112 Vilseck Road in Fort Stewart. There will be refreshments, giveaways, ... have the opportunity to meet general dentists Thomas Richards, DDS, and Josh Faulk, DMD, ...
(Date:4/29/2016)... Philadelphia, PA (PRWEB) , ... April 29, 2016 ... ... Pennsylvania announced that student team BioCellection won the $30,000 Perlman Grand Prize of ... Impact Prize, the Gloeckner Undergraduate Award, the Michelson People‚Äôs Choice Award, and the ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Association (CCA), is pleased to announce the launch of the GFCP Scoop ... recipes, and more. The purpose of the GFCP Scoop site is ...
(Date:4/29/2016)... ... ... based oral and maxillofacial surgeon Dr. Majid Jamali is an expert in ... Dr. Jamali is proud to offer this permanent solution to patients who suffer from sleep ... This surgery is performed to correct the alignment of the jaw. It is beneficial for ...
Breaking Medicine News(10 mins):